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Abstract 
Background: Serine–arginine rich splicing factor 2 (SRSF2) is a protein known for its role in RNA splicing and genome 
stability. It has been recently discovered that SRSF2, along with other splicing regulators, is frequently mutated in 
patients with myelodysplastic syndrome (MDS). The most common MDS mutations in SRSF2 occur at proline 95; the 
mutant proteins are shown to have different RNA binding preferences, which may contribute to splicing changes 
detected in mutant cells. However, the influence of these SRSF2 MDS‑associated mutations on specific splicing events 
remains poorly understood.
Results: A tetracycline‑inducible TF‑1 erythroleukemia cell line was transduced with retroviruses to create cell lines 
expressing HA‑tagged wildtype SRSF2, SRSF2 with proline 95 point mutations found in MDS, or SRSF2 with a deletion 
of one of the four major domains of the protein. Effects of these mutants on apoptosis and specific alternative splic‑
ing events were evaluated. Cells were also treated with DNA damaging drugs for comparison. MDS‑related P95 point 
mutants of SRSF2 were expressed and phosphorylated at similar levels as wildtype SRSF2. However, cells expressing 
mutant SRSF2 exhibited higher levels of apoptosis than cells expressing wildtype SRSF2. Regarding alternative splic‑
ing events, in nearly all examined cases, SRSF2 P95 mutants acted in a similar fashion as the wildtype SRSF2. How‑
ever, cells expressing SRSF2 P95 mutants had a percent increase in the C5 spliced isoform of cell division cycle 25C 
(CDC25C). The same alternative splicing of CDC25C was detected by treating cells with DNA damaging drugs, such as 
cisplatin, camptothecin, and trichostatin A at appropriate dosage. However, unlike DNA damaging drugs, SRSF2 P95 
mutants did not activate the Ataxia telangiectasia mutated (ATM) pathway.
Conclusion: SRSF2 P95 mutants lead to alternative splicing of CDC25C in a manner that is not dependent on the 
DNA damage response.
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Background
Serine–arginine rich splicing factor 2 (SRSF2), previ-
ously named SC35, is a member of the SR protein fam-
ily of splicing regulators. The primary role of SR proteins 
is to regulate splice site selection for both constitutive 
and alternative splicing. In addition to their role in splic-
ing, SR proteins are also involved in the maintenance 
of genome stability through the prevention of R-loop 
structure formation during transcription [1–4]. Structur-
ally, SRSF2 can be divided into specific protein domains 
(Fig. 1a). The RNA recognition motif (RRM) is involved 
in binding to exonic or intronic splicing enhancers in 
the nascent pre-mRNA transcript. The eponymous ser-
ine–arginine rich domain (RS) is primarily involved in 
protein–protein interactions with other spliceosomal 
components and with the 7SK complex involved in tran-
scriptional elongation [3, 5, 6]. In addition, serine phos-
phorylation at the RS domain significantly affects the 
subnuclear localization and functions of SRSF2 [7–11]. 
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The short amino acid sequence between the RRM and 
RS domains is the hinge region (HNG). The exact func-
tion of this region is largely unknown, though studies 
with SRSF1 (ASF/SF2) suggest that it may have an impor-
tant role in kinase docking [12]. The last major domain 
of SRSF2 is the nuclear retention signal (NRS) at the 
C-terminal end of the protein, which is unique to SRSF2. 
Deletion of this NRS allows SRSF2 to shuttle between the 
nucleus and cytoplasm, similar to the shuttling function 















































Fig. 1 Expression and phosphorylation of SRSF2 P95 and deletion mutants. a Schematic of SRSF2HA ORF showing the primary protein domains 
removed to create SRSF2 deletion mutants. RRM RNA recognition motif; HNG hinge region; RS arginine/serine‑rich domain; NRS nuclear retention 
signal; HA hemagglutinin tag. Numbers denote amino acids defining the domain boundaries within the full length protein. Location of the P95 
amino acid within the hinge region is denoted with a large red arrow. b Western blot of protein isolated from cell lines after 48 h doxycycline induc‑
tion. c Average HA‑tagged protein expression in induced cell lines, normalized to GAPDH expression. Statistics are based on one‑way analysis of 
variance (ANOVA) with comparison to SRSF2WT cell line (n = 5). d qRT‑PCR analysis of HA‑tagged SRSF2 mRNA expression, normalized to SRSF2WT. 
No statistical significance using one‑way ANOVA with comparison to SRSF2WT (n = 4). e Western blot using anti‑HA and anti‑ phospho‑SR antibod‑
ies after immunoprecipitation of HA‑tagged SRSF2 protein. f Analysis of phospho‑SR signal normalized to HA‑tagged protein signal. Statistics use 
one‑way ANOVA with comparison to SRSF2WT (n = 3). p values: *≤0.05; **≤0.01; ***≤0.001; ****≤0.0001
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It was recently discovered that SRSF2 is mutated in 
10−15  % of patients with Myelodysplastic syndrome 
(MDS) and 25–30 % of patients with chronic myelomono-
cytic leukemia (CMML) [13–19]. Both of these diseases 
are aging-associated hematopoietic disorders that occur 
primarily in individuals over the age of 60 [20]. The only 
effective long term treatment for either disease is a bone 
marrow transplant, which is often not possible to perform 
due to both the age of the patients and a high relapse rate 
in patients with advanced disease [21–24]. While the cause 
of these disorders is still unknown, alternative splicing in 
genes related to hematopoiesis and cell cycle regulation, 
such as CDC25C and RUNX1, have been found in patients 
with MDS or AML [25, 26]. For both of these diseases, 
patients with SRSF2 mutation have a miscoding of the pro-
line at position 95 (P95) to a histidine, arginine, or leucine 
during the early stages of the disease. These mutations per-
sist throughout the disease [18, 27]. Recent research has 
also shown that P95 mutations of SRSF2 affect the ability of 
SRSF2 to bind its canonical splicing enhancer sequences in 
RNA [28, 29]. In addition, the P95H mutation of SRSF2 can 
increase death of hematopoietic cells and cause changes in 
hematopoiesis [28, 30]. Results from these studies support 
the notion that these mutations of SRSF2 are involved in 
MDS pathogenesis. However, the mechanism for how these 
mutations lead to disease development is still unknown.
We have constructed stable cell lines expressing from a 
Tet-inducible promoter HA-tagged wildtype SRSF2 (SRS-
F2WT), HA-tagged SRSF2 with point mutations found in 
patients with MDS (SRSF2P95H, SRSF2P95L, and SRSF2P95R), 
and HA-tagged SRSF2 with in-frame deletions of each of 
the four major domains of the protein (SRSF2ΔRRM = dele-
tion of the RNA recognition motif, SRSF2ΔHNG = deletion 
of the hinge region, SRSF2ΔRS = deletion of the arginine/ser-
ine-rich domain, and SRSF2ΔNRS = deletion of the nuclear 
retention signal) in TF-1 erythroleukemia cells (Fig.  1a). 
Our data showed that while the SRSF2P95R/L/H mutations 
did not affect cellular localization of the protein, they did 
increase early apoptosis and affect the alternative splicing 
of CDC25C towards a shorter isoform (CDC25C-C5) that 
has previously been shown to be upregulated when DNA is 
damaged in breast cancer cells exposing to sub-lethal levels 
of doxorubicin and cisplatin [31]. Interestingly, we found 
SRSF2 mutant induced alternative splicing of CDC25C does 
not require activation of the DNA damage response path-
way that is activated with cisplatin treatment.
Methods
Plasmid construction
The pRevTRE-SC35HA (SRSF2HA) tet-inducible plas-
mid was a gift from Xiang-Dong Fu’s lab at UCSD 
[2]. Mutations of P95 were produced using site-
directed mutagenesis with the QuikChange Kit (Agi-
lent) with the following primers: SRSF2-P95X sense 
(5′-CTACGGCCGCCDCCCGGACTCAC-3′) and 
SRSF2-P95X antisense (5′-GTGAGTCCGGGHG-
GCGGCCGTAG-3′), where D is A, T, and G and 
H is A, T, and C [32]. SRSF2 deletion mutants were 
produced using the InFusion cloning system (Clon-
tech) and primers that overlapped the deletion sites: 
ΔRRM F1 (ATGTGGAGGGTATGACCTCCATG-
GCGCGCTACGGC), ΔRRM R1 (GCCGTAGCGCGC-
CATGGAGGTCATACCCTCCACAT), ΔHNG F1 
(CGAGCTGCGGGTGCAAAGCCGCCGGGGACC), ΔHNG R1 (GGTCCCCG-
GCGGCTTTGCACCCGCAGCTCG), ΔRS F1 (CCCG-
GACTCACACCACCCTCCCCCAGTGTCCA), ΔRS R1 
(TGGACACTGGGGGAGGGTGGTGTGAGTCCGGG), ΔNRS 
F1 (GGTCTCGGTCCAGGAGTCTCGAGTACCCAT-
ACGACG), ΔNRS R1 (CGTCGTATGGGTACTCGAGA-
CTCCTGGACCGAGACC). SRSF2HA gene sequence 
was confirmed using Sanger sequencing. The lentiviral 
plasmid for expression of the reverse Tet transactivator 
protein (pHIV7-rtTA-V15), the plasmids for lentiviral 
packaging (pC-GP, pCMV-rev, pCMV-G), and the plas-
mids for retrovirus packaging (pCMV-GP and pCMV-G) 
were gifts from the lab of Jiing-Kwan Yee at City of Hope.
Production and transduction of lentivirus and retrovirus
For the rtTA lentivirus, 293T cells were transfected with 
pHIV7-rtTA, pC-GP-2, pCMV-rev2, and pCMV-G using 
calcium phosphate [32]. After 48  h, cell supernatant 
was collected, filtered through a 0.45 µm filter, and pre-
cipitated in a 10 % PEG solution overnight at 4 °C. Virus 
was then concentrated by centrifuging the PEG solution 
30  min at 2000×g. Supernatant was decanted and virus 
pellet was resuspended in the remaining solution. Virus 
was tittered on HT1080 cells by G418 resistance. TF-1 
cells were transduced with rtTA lentivirus at an MOI of 
0.003 for 48 h and then diluted to single cells and plated 
in 96-well plates for G418 selection. Single clones were 
collected and assayed for doxycyline induction potential. 
Clone #6 was chosen as the TF-1 TetON parental cell 
line.
For the SRSF2HA retroviruses, 293T cells were trans-
fected with the respective pRevTRE-SRSF2HA plasmid, 
pCMV-GP, and pCMV-G sing calcium phosphate trans-
fection. After 48  h, virus was collected as above. Virus 
was tittered on HT1080 cells by hygromycin B selection. 
TF-1 TetON cells were transduced with resulting retro-
viruses at an MOI of 0.1 for 48 h. Each group was then 
selected for 2 weeks using hygromycin B to produce the 
TF-1 TetON SRSF2HA cell lines.
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cDNA synthesis and RT‑PCR
1  ×  106 cells were pelleted and resuspended in 100  µl 
Trizol. After 5  min incubation, 100  μl 100  % EtOH was 
added and RNA was isolated using Direct-zol kit (Zymo 
Research). 1 µg RNA was used for cDNA synthesis using 
either SuperScript III RT (Invitrogen) or PrimeScript RT 
(Clontech). Each RT-PCR reaction contained 10  μl 2× 
Taq (BioPioneer), 0.5  µM each primer, and 1  μl cDNA. 
Primer list and reaction conditions can be found in Addi-
tional file 1: Table S1.
Western Blot Analysis
1 × 106 cells were washed 1× with PBS and then resus-
pended in 50  µl dH20. 50  µl 2× Laemmli buffer, pre-
warmed to 85  °C, was added to each sample. Samples 
were incubated 10 min at 95  °C. Samples were then ali-
quoted and flash frozen in liquid nitrogen to be stored 
at −80 °C. For SDS-PAGE, samples were diluted 3.5-fold 
using 1× Laemmli buffer, and 7 μl was loaded per lane. 
Following SDS-PAGE, proteins were transferred to PVDF 
membrane. The membranes were blocked for 1 h at RT 
with either 5 % (w/v) nonfat dry milk in TBST (50 mM 
Tris–Cl, pH 7.5. 150  mM NaCl, 0.1  % Triton X-100) or 
3  % (w/v) BSA in TBST. Membranes were washed 3× 
with TBST. Primary antibodies [rabbit anti-HA tag 
(Abcam; ab9110; 1:10,000), mouse anti-GAPDH (Inv-
itrogen; ZG003; 1:5000), mouse anti-SR proteins [1H4] 
(Santa Cruz Biotech; sc-13,509; 1:200), rabbit anti-
CDC25C [E303] (GeneTex; GTX61135; 1:500), rabbit 
anti-phospho CHK2 (Cell Signaling Technology; 2661; 
1:2000), and mouse anti-phospho p53 [16G8] (Cell Sign-
aling Technology; 9286; 1:500)] were diluted as stated in 
TBST and incubated overnight at 4 °C. Membranes were 
washed 3× with TBST. Secondary antibodies [goat anti-
rabbit IgG-IRDye 680LT (Li-Cor; 926-68021; 1:20,000), 
goat anti-mouse IgG-IRDye 800CW (Li-Cor; 926-32,210; 
1:20,000), goat anti-rabbit-HRP (BioRad; 170–6515; 
1:3000), and goat anti-mouse-HRP (BioRad; 170–6516; 
1:3000)] were diluted as stated in TBST and incubated 
with the membranes for 4  h at RT. Membranes were 
washed 3×, 5 min each wash, and subsequently scanned 
with an Odyssey machine (for Li-Cor secondaries) or 
exposed to X-ray film (for HRP secondaries).
Immunoprecipitation
1  ×  107 cells were pelleted for 5  min at 400×g. Super-
natant was removed and cells were resuspended in a 
buffer containing 50 mM HEPES (pH 7.8), 3 mM MgCl2, 
300 mM NaCl, 1 mM DTT, 0.1 mM PMSF, 1X Halt™ Pro-
tease Inhibitor Cocktail (Thermoscientific), 5  mM NaF, 
2  mM NaVO3, 0.5U/µl DNase I, and 5U/µl benzonase. 
Samples were incubated at 4  °C for 1  h with constant 
rotation, after which samples were centrifuged for 3 min 
at 4  °C, 10,000×g. Supernatant was added to 50 μl anti-
HA agarose beads (Sigma) and total volume was brought 
to 200 μl with TBS. Samples were incubated overnight at 
4 °C with constant end-over-end rotation. Agarose beads 
were pelleted for 10  s at 16,000g, and supernatant was 
removed as the unbound fraction. Pellet was washed 5× 
with TBST. Samples were eluted by incubating agarose 
beads with 50 µl 1 mg/ml HA peptide (ThermoFisher Sci-
entific) at 30 °C for 15 min. Eluate was assayed by West-
ern blot.
Immunofluoresecence
Glass coverslips (Fisher Scientific; 22  ×  22–1.5) were 
incubated with 0.01 % poly-l-lysine (Sigma) for 10 min. 
Poly-l-lysine solution was removed and coverslips were 
air-dried. 2 × 105 cells were incubated on coverslips 1 h 
at 37  °C. Coverslips were washed 2× with PBS. Cells 
were fixed by incubating coverslips with 4 % (w/v) para-
formaldehyde in PBS for 20  min at RT. Coverslips were 
then washed 2× with PBS and incubated 15  min at RT 
with 0.1 % (v/v) Triton X-100 in PBS. Cells were blocked 
by incubating coverslips overnight at 4  °C in 10  % (v/v) 
FBS in PBS. Coverslips were incubated with primary 
antibodies [rabbit anti-HA tag (Abcam; ab9110), mouse 
anti-SC35 (Abcam; ab11826), and mouse anti-γH2AX 
(ab11174)] each diluted 1:100 in the blocking solution 
for 1 h at RT. Coverslips were washed 5× with PBS and 
then incubated 1  h at RT with secondary antibodies 
[goat anti-rabbit IgG-AF647 (Jackson ImmunoResearch; 
111-605-003) and goat anti-mouse IgG-AF488 (Jack-
son ImmunoResearch; 115-545-003)] diluted 1:100 in 
the blocking solution. Coverslips were then washed 5× 
with PBS and incubated 10 min at RT with 1× CellMask 
Orange (LifeTechnologies). Coverslips were then washed 
3× with PBS and mounted on glass slides using VectaSh-
ield Hardset Mounting media with DAPI (Vector Labo-
ratories). Slides were incubated overnight at 4  °C before 
imaged using a Zeiss LSM 700 confocal microscope. 
Analysis for HA-tagged protein localization was done 
using Image-Pro Plus (Media Cybernetics). The whole 
cell area was outlined in the Cell Mask Orange channel 
image and copied into the HA protein channel image. 
The nucleus was outlined in the DAPI channel image and 
also copied into the HA protein channel image. The inte-
grated optical density (IOD) was analyzed independently 
for the whole cell and nucleus. The IOD for the cyto-
plasm alone was calculated by subtracting the IOD for 
the nucleus from the IOD of the whole cell.
Apoptosis assay
1  ×  105 cells were washed 1× with PBS. Cells were 
stained for 15  min using FITC-Annexin V and PI from 
FITC Annexin V Apoptosis Kit I (BD Pharmigen). 
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Samples were then analyzed on a Cyan FACS machine. 
Cells were considered to be apoptotic based upon posi-
tive FITC detection. The stage of apoptosis was deter-
mined by the level of PI staining of the FITC-positive 
cells. Early apoptosis lacked any PI staining. Middle 
apoptosis had positive, albeit low levels of, PI staining. 
Late apoptosis was defined by high levels of PI staining.
Cell proliferation assay
5 × 106 cells were stained on day 0 in 10 µM CFSE (car-
boxyfluorescein succinimidyl ester, Thermo Fisher Scien-
tific) for 15 min at 37 °C. Each day including day 0, half of 
the cell culture was removed from the flask, washed 2× 
with PBS, fixed for 15 min in 4 % (w/v) paraformaldehyde 
in water, washed 2× with PBS, and stored at 4 °C in the 
dark. After all time points for a single biological replicate 
were collected, samples were analyzed on a Cyan FACS 
machine. Data are plotted by using CFSE log mean.
Cell cycle analysis
1 × 106 cells were washed 2× with PBS. Cells were resus-
pended in 500  µl ice-cold 80  % EtOH and incubated 
overnight at 4  °C. Cells were washed 2× with PBS, and 
resuspended in 0.25  % Triton X-100, 20  µg/ml PI (pro-
pidium iodide), and 0.1 ng/ml RNase A. Cells were incu-
bated overnight at 4 °C. Samples were analyzed on a Cyan 
FACS machine. Data were analyzed using the cell cycle 
tool in FlowJo v6.
Results
Characterization of SRSF2‑HA‑expressing cell lines
We started our study by engineering a TF-1 TetON cell 
line. The TF-1 cell line was chosen due to its classifica-
tion as an erythroblast, allowing for inducible expression 
of an HA-tagged SRSF2 in a cell type similar to those 
commonly affected in MDS patients in order to examine 
phenotypic changes that may occur as a result of SRSF2 
mutations. Furthermore, by PCR and Sanger sequenc-
ing, none of the common MDS-related mutations in 
U2AF1(S34), SF3B1(K700), or SRSF2(P95) were detected 
in the parental TF-1 cell line (data not shown).
We used site directed mutagenesis to produce eight dif-
ferent SRSF2 constructs: wildtype (SRSF2WT), each of the 
three MDS- and CMML-related point mutations (SRS-
F2P95H, SRSF2P95L, and SRSF2P95R), and four deletions 
for each of the primary domains of SRSF2 for compari-
son (SRSF2ΔRRM, SRSF2ΔHNG, SRSF2ΔRS, and SRSF2ΔNRS) 
(Fig. 1a).
In order to assay for transgene expression, each of the 
SRSF2 cell lines (WT, P95H, P95L, P95R, ΔRRM, ΔHNG, 
ΔRS, and ΔNRS) and the parental TF-1 TetON cell line 
were cultured for 48  h, both with and without induc-
tion using 2  μg/ml doxycycline. After 48  h, protein and 
RNA were isolated from each line. Western blotting 
using anti-HA antibodies detected the expression of HA-
tagged proteins with the expected size for each construct 
upon doxycycline induction (Fig.  1b). A small amount 
of the HA-tagged protein was expressed from the mini-
mal CMV promoter without doxycycline induction 
(Additional file  2: Figure S1). The expression levels for 
SRSF2ΔRRM, SRSF2ΔHNG, and SRSF2ΔRS were noticeably 
lower than others (Fig. 1b, c). qRT-PCR of the ectopically 
expressed SRSF2-HA mRNAs showed no significant dif-
ferences in the RNA level between the WT and mutants 
(Fig. 1d). Therefore, it appears that a deletion of the RRM, 
HNG, or RS domain negatively affects protein stability 
and/or efficient translation.
Since the hinge region of SRSF1 is required for kinase 
docking [12], we wanted to determine whether the 
disease-related P95 mutations of SRSF2, which occur 
in the hinge region, would affect the phosphorylation 
level of SRSF2. To this end, we immunoprecipitated the 
HA-tagged SRSF2 using an antibody against the HA 
tag. Western blots of the immunoprecipitated samples 
showed that SRSF2P95H, SRSF2P95L, and SRSF2P95R were 
phosphorylated to the same level as SRSF2WT, as meas-
ured by anti-phospho-SR antibody (1H4 monoclonal 
antibody) while none of the deletion mutants showed 
detectable levels of phosphorylation (Fig. 1e, f ).
As stated previously, unlike other SR proteins that are 
shuttled between the nucleus and the cytoplasm, SRSF2 
is confined to the nucleus [9]. To examine whether any 
of the mutations would affect the cellular localization 
of SRSF2, we stained the tet-induced cells with anti-HA 
antibodies. Immunofluorescence results from the anti-
HA staining showed that SRSF2WT, SRSF2P95H, SRS-
F2P95L, SRSF2P95R, SRSF2ΔRRM, and SRSF2ΔHNG were all 
confined to the nucleus (Fig. 2a; Additional file 3: Figure 
S2a). SRSF2ΔNRS was located in both the nucleus and 
cytoplasm in agreement with previous studies showing 
that deletion of the NRS allows SRSF2 to shuttle between 
the nucleus and cytoplasm [9]. Unexpectedly, SRSF2ΔRS 
was also present in both the nucleus and cytoplasm 
when it was expected to be located only in the cytoplasm 
due to loss of the primary nuclear localization signal 
[9, 33–35]. It is possible that the remaining presence of 
the NRS allows for partial nuclear localization. We also 
stained each of the cell lines with an anti-SC35 antibody 
that specifically stains the nuclear phosphorylated SC35 
speckles [33, 36]. Previous research has shown that the 
phosphorylation state determines whether SRSF2/SC35 
is localized within nuclear speckles [10]; therefore the 
pan-nuclear staining of HA-tagged SRSF2 indicated that 
a substantial portion of the HA-tagged protein is not 
in a phosphorylation state reserved for speckle locali-
zation. We also observed nuclear SC35-speckles with 
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similar sizes and numbers among the cell lines, indicat-
ing the expression of the SRSF2-HA proteins did not sig-
nificantly alter the formation or the dynamics of nuclear 
speckles (Fig. 2a).
Factors that can initiate an apoptotic signaling cascade, 
such as Fas, Fas-L, tumor necrosis factor-a, and tumor 
necrosis factor-related apoptosis initiating ligand, are 
upregulated in bone marrow cells of MDS patients [37, 
38], and it is thought that this increase in apoptosis in the 
bone marrow may contribute to the cytopenias that are a 
hallmark of MDS [39]. To assay our cell lines for changes 
in apoptosis, FITC-Annexin V and propidium iodide 
(PI) staining were used to determine apoptosis levels in 
each of the TF-1 cell lines (Additional file 3: Figure S2b). 
Without doxycycline induction, there was no significant 
difference in apoptosis levels between any of the cell lines 
(Fig. 2b). However, with the doxycycline-induced expres-
sion of any of the three P95 mutant SRSF2 transgenes, 
cells showed a significant increase in early/middle apop-
tosis as compared to the SRSFWT and parental TetON 
cell lines (Fig.  2c). This result suggests that SRSF2 P95 
mutations may be pro-apoptotic. We also noticed that 
SRSF2ΔHNG, SRSF2ΔRS, and SRSF2ΔNRS expressing cells 
also showed an increase in early/middle apoptosis as 
compared to the control cell lines, whereas SRSF2ΔRRM 
showed no effect on apoptosis. We have also measured 
cell proliferation using CFSE staining. Upon staining, 































Fig. 2 Apoptosis and subcellular localization of P95 and deletion SRSF2 mutants. a Representative immunofluorescence images of SRSF2HA cell 
lines (n = 3). CellMask Orange stained cytoplasm, DAPI stained DNA in the nucleus, anti‑SC35 speckle marker stained SC35/SRSF2 in the nuclear 
speckles, anti‑HA stained HA‑tagged SRSF2 protein. b Average percentage of cells in early or late apoptosis at 48 h in the absence of doxycycline 
induction. c Average percentage of cells in early or late apoptosis at 48 h post‑doxycycline induction. Statistics use two‑way ANOVA with compari‑
son to TF‑1 TetON (n = 4). Asterisks are p values as in Fig. 1
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proteins, and as the cells divide the existing CFSE-bound 
proteins are redistributed to the daughter cells resulted in 
decreasing CFSE staining per cell. Thus, cell proliferation 
can be accurately measured by monitoring CFSE stain-
ing in cell culture [40]. By using CFSE staining, we did 
not observe significant change of cell proliferation with 
any of the SRSF2 mutants (Additional file 3: Figure S2c). 
Thus, increased apoptosis in SRSF2P95H/L/R is consistent 
with increased apoptosis of MDS cells.
Alternative splicing changes
SRSF2 is known to regulate alternative splicing of a num-
ber of pre-mRNAs including its own [41]. There are six 
splice variants of SRSF2 described in the database, and 
four of them were detected by RT-PCR in TF-1 cells 
using the primers depicted (Fig.  3a, b). Among these, 
splice isoforms v3, v4, and v6 are substrates of nonsense-
mediated decay (NMD) because they all have at least 
one intron that is more than 50 nucleotides downstream 
from the stop codon (Fig.  3a) [42]. The splice variant 5 
(v5) has an intron 7 nucleotides downstream from the 
stop codon, which does not activate NMD, and is the 
predominant RNA species (Fig. 3b). As previously shown 
[41], SRSF2WT overexpression promoted inclusion of 
alternative exons and resulted in an increase in isoform 
4 expression as detected by RT-PCR (Fig. 3b, c). Similarly, 
expression of a P95 point mutant (SRSF2P95H, SRSF2P95L, 
or SRSF2P95R) also led to an increase of v4, indicating that 
these P95 mutations of SRSF2 do not affect its ability to 
auto-regulate its exon inclusion. On the contrary, expres-
sion of the RRM, RS, or HNG deletion mutants did not 
cause a significant increase of v4, while expression of 
SRSF2ΔNRS did (Fig. 3c). This supports previous findings 
that deletion of the NRS does not affect the alternative 
splicing function of SRSF2, whereas both the RRM and 
RS domains are required for this function [9, 33, 43–45].
We next investigated whether any of the SRSF2 
mutants would alter splicing of other mRNAs that have 
been previously shown to be affected by SRSF2. To begin 
with, E2F1-mediated overexpression of SRSF2 has been 
shown to promote alternative splicing of a set of apop-
tosis-related genes to their pro-apoptotic form [46]. We 
assayed alternative splicing of BCL-X, caspase-8, and cas-
pase-9 by RT-PCR. At 48  h post-induction, we did not 
observe significant changes in alternative splicing in any 
of the SRSF2-expressing TF-1 cell lines (Additional file 4: 
Figure S3). Next, we assayed splice variants of BAP1 and 
TRA2A, which are found to change in mouse fibroblasts 
upon SRSF2 knock out [47]. We observed no significant 
splicing changes in these genes with doxycycline-induced 
overexpression of SRSF2WT or any of the SRF2 mutants 
in TF-1 cells (Additional file 5: Figure S4).
We then analyzed the alternative splicing of CDC25C, 
a dual-specific phosphatase critical for the G2/M check-
point pathway of the cell cycle. CDC25C has previously 
been found to be alternatively spliced in the bone marrow 
of patients with MDS [25]. In addition, CDC25C is part 
of the common deleted region in 5q- syndrome, the only 
subtype of MDS that has a defined cytogenetic cause and 
effective chemotherapy treatment [48–51]. Furthermore, 
haploinsufficiency of CDC25C is required for effective 
lenalidomide treatment of patients with 5q- syndrome 
[52]. RT-PCR analysis of CDC25C revealed a distinctive 
change in the levels of the C5 isoform, which lacks exons 
3, 5, and 6, relative to C1 among the SRSF2 mutants. Spe-
cifically, expression of the MDS-associated point mutants 
(SRSF2P95H, SRSF2P95L, and SRSF2P95R) each caused an 
increase in the CDC25C C5/C1 ratio (Fig. 4b, c). In con-
trast, expression of SRSF2WT or the deletion mutants did 
not affect this ratio.
We then considered that this alternative splicing 
change may cause expression of a truncated CDC25C 
protein. Western blotting using an anti-CDC25C anti-
body, specific for the C-terminus of the protein, detected 
the  ~60  kDa CDC25C C1 protein and an increased 
expression of a smaller protein isoform that corresponds 
to the expected ~45  kDa CDC25C C5 protein (Fig.  4d, 
e). This result indicated that expression of SRSF2P95H, 
SRSF2P95R, or SRSF2P95L causes a splicing change of 
CDC25C mRNA, whereas expression of the SRSF2 dele-
tion mutants or the wild-type protein does not produce 
the alternative splicing change.
CDC25C alternative splicing and the DNA damage 
response
The elevated ratio of CDC25C C5/C1 detected in our 
TF-1 SRSF2-P95 mutants, has also been reported to be 
induced in breast cancer cells by treatment with sublethal 
doses of DNA-damaging agents, such as cisplatin (CIS) 
and doxorubicin [31]. To test whether DNA damaging 
agents would also alter alternative splicing of CDC25C 
in hematopoietic cells like TF-1, we treated TF-1 cells 
with various concentrations of CIS. As shown in Fig. 5a, 
b the ratio of C5/C1 indeed increased when cells were 
treated with 40–50 μM of CIS for 12 h. CIS forms DNA 
crosslinks that can cause double-stranded breaks that 
activate the DNA damage response via the ATM pathway 
[53–55]. We also tested other drugs that induce the ATM 
DNA damage response pathway: camptothecin (CPT), a 
topoisomerase I poison that causes chromosomal breaks 
[56–58], and trichostatin A (TSA), a histone deacetylase 
inhibitor [59, 60]. Similar to the effects observed with CIS 
treatment, CPT at 20–200 nM for 6 h or TSA at 5–20 μM 
for 12 h also caused an increase of the C5 splice variant of 
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CDC25C (Fig. 5c, d; Additional file 6: Figure S5a, b). We 
noticed that some RT-PCR signals were weak or barely 
detectable—this was evident in RNA samples from cells 
treated with high drug doses or extended time—likely 
resulted from low RNA yields under those conditions. 
Similar weak RT-PCR signals were also observed and 
used to quantify the ratio of C5 to C1 in heavily treated 
cells by Albert et  al. [31]. We also analyzed the protein 
levels of the CDC25C isoforms by immune-blotting and 
found evidence consistent with a percent increase of the 
C5 protein isoform in cells treated with CIS, CPT, or 
TSA at a dosage that caused CDC25C alternative splicing 
(Additional file 6: Figure S5c, d).
Since agents that activate the ATM-mediated DNA 
damage response cause a similar splicing change (ele-
vated CDC25C C5/C1) as the MDS-associated SRSF2 
mutants, we wondered whether these point mutants 
may also activated the ATM-mediated DNA damage 
response. To test this, we examined whether the phos-
phorylation of ATM substrates (p53, CHK2, and H2A.X 
[61–68]) increases in the drug-treated cells and/or in the 
SRSF2 mutant expressing cells. Cell lysates were analyzed 
using Western blotting for phospho-p53 and phospho-
pCHK2. Treatment of the TF-1 TetON cell line with CIS, 
CPT, or TSA led to an increase in both phospho-p53 and 
phospho-CHK2 compared to untreated TF-TetON cells, 




























Fig. 3 Alternative splicing at the 3′UTR of endogenous SRSF2 transcripts. a Schematic of previously described SRSF2 isoforms (splice variants 3, 4, 5, 
and 6) that result from alternative splicing of the 3′UTR. Yellow arrows depict general location of primers used in RT‑PCR. b Representative gel from 
RT‑PCR of endogenous SRSF2′s 3′UTR after 48 h treatment with 2 μg/ml doxycycline. The sizes in base pairs of the PCR products corresponding to 
the splice variants are labeled on the right. c Bar graphs depicting changes in  % isoform 4 (v4) of total RNA. Statistics are based on two‑way ANOVA 
with comparison to SRSF2WT (n = 4). Asterisks are pvalues as in Fig. 1; note that the data were compared to the WT and not to the tetON
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as expected (Fig.  5e). However, ectopically expressing 
SRSF2 in TF-1 cells did not show a significant increase 
in phospho-p53 or phospho-CHK2 compared to dox-
ycyline-treated TF-1 TetON, regardless of whether the 
SRSF2 was WT or a P95 mutant. We also tested levels of 
γH2A.X phosphorylation, a general marker for genome 
instability [69], in each of these cell lines. Again, CIS, 
CPT, and TSA treatment each increased γH2A.X lev-
els while none of the SRSF2 cell lines had an increase in 
γH2A.X (Fig.  5e; Additional file  7: Figure S6). In addi-
tion, by propidium iodide staining, none of the MDS-
related point mutants induced G2/M arrest (Additional 
file  8: Figure S7a). To test whether apoptosis played a 
role in CDC25C alternative splicing, we added caspase 
inhibitor zVAD to block apoptosis in cells expressing 
SRSF2-P95 mutants. The ratio between splice variant 
C5 and C1 increased when SRSF2-P95 mutant expres-
sion was induced as expected; however, the addition of 
zVAD had no observable effect on CDC25C alternative 
splicing regardless whether SRSF2-P95 mutant expres-
sion was induced or not (Additional file 8: Figure S7B, C). 
This result indicated that apoptosis, although occurred 
in SRSF2-P95 mutant cells, was not responsible for the 
CDC25C alternative splicing. Taken together, it appears 
that the induction of CDC25C alternative splicing by 
MDS-related SRSF2 point mutations does not require 
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Fig. 4 Alternative splicing of CDC25C in SRSF2 mutant cell lines. a Schematic of previously described five CDC25C isoforms. Black is the CDC25C 
RNA with all 14 exons (the exon boundaries are marked). The general locations for the N‑terminal regulatory domain and the C‑terminal catalytic 
domain, as well as the RT‑PCR primers, are annotated. Dark blue is the known CDC25C alternative splicing transcripts. Gray depicts areas of frame 
shift that occurs with alternative splicing change in C3, C4, and C5. b Representative gel from RT‑PCR of CDC25C after 48 h treatment with 2 μg/ml 
doxycycline. The sizes in base pairs of the PCR products corresponding to the splice variants are marked on the right. c Bar graphs depicting ratio of 
C5/C1 isoforms. Statistics are based on two‑way ANOVA with comparison to SRSF2WT (n = 5). d Western blot depicting CDC25C protein expression 
in the presence of doxycyline induction. e Graph depicting the Western results shown in D for CDC25C protein expression at 48 h post‑induction. 
Statistics are based on two‑way ANOVA with comparison to SRSF2WT (n = 5). Asterisks are p values as in Fig. 1
Page 10 of 14Skrdlant et al. BMC Molecular Biol  (2016) 17:18 
Discussion
Known functions of SRSF2 include regulation of con-
stitutive and alternative splicing and maintenance of 
genome stability through the prevention of transcrip-
tion-related R-loops [2, 3, 70]. Nearly half of all patients 
with MDS have mutation in a gene that regulates splic-
ing. One of the most common mutations is the point 
mutation of proline 95 of SRSF2 to histidine, leucine, or 
arginine, which occurs in 15–20  % of all MDS patients. 
Recent research has shown that this mutation affects the 
RNA recognition specificity of SRSF2 and that the P95H 
mutation in a mouse model correlates with a phenotype 
similar to MDS [28–30]. However, the effect of SRSF2 
mutation on distinct alternative splicing events remains 
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Fig. 5 Drug‑induced CDC25C alternative splicing. a Representative RT‑PCR gel of alternative splicing of CDC25C in response to cisplatin treatment. 
(b to d) Line graph depicting average C5/C1 ratios for CDC25C in TF‑1 TetON cells treated with b cisplatin, c CPT, and d TSA treated TF‑1 TetON cells. 
Statistics are determined by two‑way ANOVA with comparison to 0 µM (n = 4). e Western blot of HA‑tagged protein, phosphorylated CHK2, phos‑
phorylated p53, and GAPDH after no treatment (lane 1), 12 h 50 µM CIS (lane 2), 6 h 200 nM CPT (lane 3), 12 h 20 µM TSA (lane 4), or 48 h doxycycline 
treatment (lanes 5–9). Asterisks are p values as in Fig. 1
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poorly understood. In this study, we show that MDS-
related SRSF2 mutants act similar to wildtype SRSF2 
in many ways, including phosphorylation and splicing 
of a select group of alternative splicing events. How-
ever, there is an alternative splicing change in CDC25C 
that is unique to SRSF2P95 mutants. Chemotherapeutics 
that induce the classical ATM DNA damage response, 
including cisplatin, camptothecin, and trichostatin A, 
also induce an identical alternative splicing change in 
CDC25C.
Recent research has shown that various types of DNA 
damage can lead to post-translational modification of 
RNA-binding proteins, many of which have roles in the 
regulation of RNA splicing [71–75]. In fact, cisplatin 
treatment has been shown to cause increased translo-
cation of SR protein kinases SRPK1 and SRPK2 to the 
nucleus leading to hyperphosphorylation of SRSF2 and 
reducing acetylation of SRSF2 [11]. In addition, activa-
tion of ATM- or ATR-mediated DNA damage response 
pathway has been shown to result in multiple changes 
in specific alternative splicing events, such as alternative 
splicing of apoptotic genes (BCL-X and caspase-8) [11, 
76], DNA damage response genes (CHK1 and CHK2) [77, 
78], and regulators of RNA splicing itself (TRA2, U2AF1, 
SRSF2 and SRSF1) [79–82]. However, the full changes in 
alternative splicing and their consequences for the DNA 
damage response still remain largely unknown.
Although it is known that CDC25C alternative splic-
ing occurs after treatment with genotoxic drugs, the 
affects of this alternative splicing on the DNA dam-
age response (DDR) and cell fate is still undetermined. 
CDC25C protein undergoes various post-translation 
modifications during the DDR in order to either induce 
the G2/M checkpoint or apoptosis. One of the major 
post-translational modifications is phosphorylation at 
Ser216 by CHK2, which leads to interaction of CDC25C 
with the 14-3-3 complex and subsequent translocation 
of the CDC25C protein to the cytoplasm [83]. With-
out CDC25C present in the nucleus to activate CDK1 
by dephosphorylation at Tyr15, the cell enters G2/M 
arrest. The C5 isoform of CDC25C is upregulated dur-
ing S phase, a cell cycle phase during which DNA repair 
frequently occurs due to DNA replication; however, the 
role of the C5 isoform in the S phase is not clear [84]. The 
alternative splicing of CDC25C, and its related protein 
CDC25A, is notable because it occurs primarily in the 
region of each transcript that encodes for the regulatory 
domain of the protein while leaving the catalytic domain 
intact (Fig. 4a) [84]. It is possible that alternative splicing 
of CDC25C, in conjunction with post-translational mod-
ification, plays an important regulatory role in cell fate 
after DNA damage. Interestingly, our results showed that 
the SRSF2 P95 point mutants cause the same alternative 
CDC25C splicing change without activating conventional 
DDR.
CDC25C is part of the commonly deleted region 
in 5q-syndrome, and effective treatment of 5q- syn-
drome with lenalidomide requires haploinsufficiency 
of CDC25C [48–52]. Furthermore, alternative splicing 
of CDC25C has already been observed in bone mar-
row samples from patients with MDS [25]. In addition, 
mutations in DNA damage response genes, such as p53 
(TP53) and ATM, are found in MDS patients without 
5-q deletion [85], and MDS-related U2AF1 mutations 
lead to alternative splicing in the DNA damage response 
genes ATR and FANCA [86]. Therefore, it appears that 
CDC25C may be recurrently misregulated in MDS 
through gene deletion, aberrant DNA damage response, 
or aberrant splicing factors like SRSF2-P95 mutants and 
U2AF1 mutants.
Conclusion
In conclusion, our data support a model where MDS-
related SRSF2 mutants lead to alternative splicing of 
CDC25C that increases the percentage of the C5 isoform 
among all the CDC25C variants. This alternative splic-
ing event can also be induced by cisplatin, camptothecin, 
or trichostatin A treatment. However, the SRSF2 point 
mutants do not lead to phosphorylation of CHK2 or p53, 
which is readily detected in the drug-treated cells. There-
fore, SRSF2P95H/L/R-mediated CDC25C alternative 
splicing changes do not require activation of the classi-
cal ATM DDR. The mechanism of CDC25C alternative 
splicing and its downstream effects may be pertinent to 
the role of SRSF2′s point mutation in the development of 
myelodysplastic syndrome.
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